Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
A systematic review on imaging-guided metastasis directed therapy for oligorecurrent prostatecancer: revolution or devolution? Metastasis directed therapy (MDT) is increasingly being implemented in recurring prostatecancer (PCa), although its role in PCa management has yet been fully defined. Aim of the current systematic review is to analyze current knowledge of MDT in the setting of recurrent PCa and highlight future trials which will continue to shed a light on a controversial aspect (...) of current PCa management.The National Library of Medicine Database was searched for relevant articles published between January 2014 and August 2019. A wide search was performed including the combination of following words: ((metastasis AND directed AND therapy) AND prostate AND cancer). The selection procedure followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) principles.Biologic studies support the use of MDT in oligometastatic PCa. Modern imaging techniques
Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic ProstateCancer: Meta-Analysis of Randomized Controlled Trials. Prostatecancer (PCa) is the sixth primary cause of cancer death. However, conflicts are present about the efficacy and safety of Non-steroidal anti-androgens (NSAA) for its treatment. The aim of this study was to assess the efficacy and safety of NSAAs versus any comparator for the treatment of advanced or metastatic PCa (mPCa).MEDLINE and the Cochrane
Green tea catechins for chemoprevention of prostatecancer in patients with histologically-proven HG-PIN or ASAP. Concise review and meta-analysis. A focused, single outcome meta-analysis on the protective role of extracts of green tea catechins against prostatecancer. Randomized, placebo-controlled studies enrolling patients with a histologically confirmed diagnosis of high-grade Prostate Intraepithelial Neoplasia or Atypical Small Acinar proliferation but no prostatecancer were included (...) in a significant reduction of cancer risk in favor of the catechin arm (risk-ratio = 0.41; 95% CI: 0.19- 0.86; I2 = 0). In conclusion, our data suggest that the intake of concentrated green tea catechin preparations may confer a significant protective effect to carriers of early neoplastic lesions in the prostate. The quality of the evidence is moderate, and additional, largescale studies are warranted to substantiate these preliminary findings.
A systematic review of the unmet supportive care needs of men on active surveillance for prostatecancer. Understanding the unmet supportive care needs of men on active surveillance for prostatecancer may enable researchers and health professionals to better support men and prevent discontinuation when there is no evidence of disease progression. This review aimed to identify the specific unmet supportive care needs of men on active surveillance.A systematic review following PRISMA guidelines
The Impact of Exercise during Radiation Therapy for ProstateCancer on Fatigue and Quality of Life: A Systematic Review and Meta-analysis. Radiation therapy (RT) is clinically proven to improve survival in men with prostatecancer. Despite these advantages, it is known to cause adverse effects such as fatigue. This review proposes to summarize the totality of evidence from randomized controlled trials regarding the effectiveness of exercise on fatigue in men with prostatecancer as a primary (...) outcome. Quality of life was a secondary outcome.RCTs that explored the effect of exercise during RT on fatigue for men with prostatecancer were searched using MEDLINE, Embase, CINAHL, Cochrane Library, AMED, ClinicalTrials.gov, and ISRTCN registry. Reference lists of included studies and reviews were also examined. Trials were excluded if they included a mixed cohort of patients where data could not be extracted for prostatecancer patients alone or if the intervention took place after RT had
Association of 17q24 rs1859962 gene polymorphism with prostatecancer risk: A systematic review and meta-analysis. Recently, several genome-wide association studies have demonstrated a cumulative association of 17q24 rs1859962 gene variants with prostatecancer (PCa) risk, but conflicting results on this issue have been reported. Hence, we performed a systematic literature review and meta-analysis to assess the association between 17q24 rs1859962 gene and PCa risk.Systematic literature searches
Comparison of prostatecancer detection rates between magnetic resonance imaging-targeted biopsy and transrectal ultrasound-guided biopsy according to Prostate Imaging Reporting and Data System in patients with PSA â‰¥4 ng/mL: a systematic review and meta Previous studies have investigated magnetic resonance imaging-targeted biopsy (MRI-TBx) on the detection for prostatecancer (PCa). Prostate Imaging Reporting and Data System (PI-RADS), as a standardized MRI reporting system, has widely been (...) used in the management of PCa. However, basing the PI-RADS score, the comparability between MRI-TBx and transrectal ultrasound-guided biopsy (TRUS-Bx) in diagnosing PCa remained inconsistent or even controversial. Thus, this systematic meta-analysis aimed to assess the value of PI-RADS in sifting better prostate biopsy method.A meta-analysis including 10 articles was performed. In these included studies, biopsy-naive subjects with concerning PSA levels and/or an abnormal digital rectal examination
Gene Expression Studies to Identify Significant Genes in AR, MTOR, MAPK Pathways and their Overlapping Regulatory Role in ProstateCancer. Gene expression studies revealed a large degree of variability in gene expression patterns particularly in tissues even in genetically identical individuals. It helps to reveal the components majorly fluctuating during the disease condition. With the advent of gene expression studies many microarray studies have been conducted in prostatecancer (...) , but the results have varied across different studies. To better understand the genetic and biological regulatory mechanisms of prostatecancer, we conducted a meta-analysis of three major pathways i.e. androgen receptor (AR), mechanistic target of rapamycin (mTOR) and Mitogen-Activated Protein Kinase (MAPK) on prostatecancer. Meta-analysis has been performed for the gene expression data for the human species that are exposed to prostatecancer. Twelve datasets comprising AR, mTOR, and MAPK pathways were
-free survival (pooled HR 1.30; 95% CI 1.10-1.54). In subgroup analyses of patients with "high-volume" and "low-volume", alkaline phosphatase was associated with the overall survival (pooled HR 1.41; 95% CI 1.21-1.64 and pooled HR 1.64; 95% CI, 1.06-2.52, respectively).In this meta-analysis, elevated serum levels of alkaline phosphatase were associated with an increased risk of overall mortality and disease progression in patients with hormone-sensitive prostatecancer. In contrast, those were (...) Prognostic value of alkaline phosphatase in hormone-sensitive prostatecancer: a systematic review and meta-analysis. To assess the prognostic value of alkaline phosphatase in patients with hormone-sensitive prostate cancer.A systematic review and meta-analysis was performed using the PUBMED, Web of Science, Cochrane Library, and Scopus in April 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared
The Relationship Between ProstateCancer and Metformin Consumption: A Systematic Review and Meta-analysis Study. Prostatecancer is the most common malignantcancer in men worldwide and after lung cancer, it is the second leading cause of cancer mortality in men. The purpose of this study was to investigate the relationship between prostatecancer and metformin consumption in men.The current study is a systematic and meta-analysis review based on the PRISMA statement. To access the studies (...) of domestic and foreign databases, Iran Medex, SID, Magiran, Iran Doc, Medlib, ProQuest, Science Direct, PubMed, Scopus, Web of Science and the Google Scholar search engine were searched during the 2009- 2018 period for related keywords. In order to evaluate the heterogeneity of the studies, Q test and I2 indicator were used. The data were analyzed using the STATA 15.1 software.In 11 studies with a sample size of 877058, the odds ratio of metformin consumption for reducing prostatecancer was estimated
PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-ProstateCarcinoma: A Systematic Review. Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostatecarcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSMA, initially developed for positron emission tomography in prostatecarcinomas (...) , are currently being explored for their staging and restaging potential as an alternative imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed. Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma, leading to a change in patient
Prognostic Value of Lactate Dehydrogenase in Metastatic ProstateCancer: A Systematic Review and Meta-analysis. The purpose of this study was to assess the prognostic value of lactate dehydrogenase (LDH) in patients with metastatic prostatecancer (PC). A systematic review and meta-analysis was performed in March 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared patients with PC with high versus low (...) , 1.01-1.16). In subgroup analyses of both patients with castration-resistant prostatecancer (CRPC) and those with hormone-sensitive prostatecancer (HSPC), LDH was associated with OS (pooled HR, 2.02; 95% CI, 1.69-2.42 and pooled HR, 2.25; 95% CI, 1.78-2.84, respectively). In patients with CRPC, LDH was associated with OS in those treated with docetaxel systemic chemotherapy and androgen receptor-axis-targeting agents (pooled HR, 2.03; 95% CI, 1.37-3.00 and pooled HR, 1.79; 95% CI, 1.25-2.57
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostatecancer patients treated with abiraterone or enzalutamide: a meta-analysis. The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostatecancer (mCRPC), whereas their prognostic values remain conflict
Reliability of the different versions of Partin tables in predicting extraprostatic extension of prostatecancer: a systematic review and meta-analysis. Accurate prediction of extraprostatic extension (EPE) of prostatecancer (PCa) is the keystone for deciding whether to perform a neurovascular bundle sparing (NVBs) radical prostatectomy or not, which will subsequently affect the postoperative functional outcomes especially potency. Partin tables are the most commonly used predictive tools (PTs
The role of cystoprostatectomy in management of locally advanced prostatecancer: a systematic review. The role of cystoprostatectomy for the treatment of locally advanced prostatecancer (LAPC) was evaluated by a comprehensive review of contemporary literatures.A systematic search of English language literatures using PubMed, EMBASE, Web of Science, and Cochrane library, from 1990 to 2018, was performed. Two independent authors reviewed abstracts as well as full-text articles and extracted (...) patients who received cystoprostatectomy combined with adjuvant therapies, 5-year cancer-specific survival rate and 5-year biochemical progression-free survival was up to 87.1% and 62.2%. Moreover, symptoms such as hematuria and other urination dysfunctions, as well as patients' quality of life were significantly improved after cystoprostatectomy in LAPC patients with the bladder invasion.Cystoprostatectomy can serve as an alternative to the surgical step of multimodal therapy for highly selected LAPC
Assessment of the clinical efficacy of simultaneous transurethral resection of both bladder cancer and the prostate: a systematic review and meta-analysis. Objective: In this study, we aimed to examine the clinical efficacy of simultaneous transurethral resection of bladder cancer and the prostate (TURBT + TURP) in non-muscle invasive bladder cancer (NMIBC) and benign prostatic hyperplasia (BPH) patients.Method: We conducted systematic research in PubMed, EMBASE, and Cochrane Library databases (...) (Qmax) (WMD, 5.92; 95% CI, 4.67-7.16; p < .001) compared with patients that underwent TURBT-only. However, rates of recurrence at the prostatic urethra/bladder neck and bladder tumor progression, as well as the time to recurrence did not differ significantly between these two groups.Conclusions: Simultaneous TURBT + TURP can be safely performed in patients with NMIBC and BPH and improves patient quality of life, without any risk of increasing tumor recurrence or metastasis rates. Comprehensive RCTs
Male circumcision and prostatecancer: A geographical analysis, meta-analysis, and cost analysis. Attempts to find an association between male circumcision and prostatecancer risk have produced inconsistent results.Age-standardized prostatecancer incidence, life-expectancy, geographical region, and circumcision prevalence from 188 countries were compared using linear regression analysis. Following a systematic literature review, a meta-analysis was performed on studies meeting inclusion (...) criteria with evaluations of between-study heterogeneity and publication bias. A cost analysis (discounted at 3% and 5% per annum) was performed using the meta-analysis's summary effect and upper confidence interval (CI).Univariate analysis revealed a trend for a positive association between country-level age-standardized prostatecancer incidence (per 100 000 person-years) and circumcision prevalence (β=0.0887; 95% CI -0.0560, +0.233) while multivariate analysis found a significant positive
PSMA PET for primary lymph node staging of intermediate and high-risk prostatecancer: an expedited systematic review. PSMA PET is a promising method for primary lymph node staging in prostatecancer. However, recent systematic reviews have identified only a limited number of studies with histopathology as a reference test.A systematic search was performed in PubMed and the Cochrane Library. An expedited systematic review was performed where we identified diagnostic studies in prostatecancer